Skip to main content

Can semaglutide and other GLP-1s cause vision loss?

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 28, 2025.

Official Answer by Drugs.com

Recent studies published in JAMA Ophthalmology have identified a potential association between semaglutide (Ozempic, Wegovy) and nonarteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause sudden vision loss. However, the absolute risk remains low, and patients should not stop taking semaglutide without consulting their healthcare provider.

Study Findings on Semaglutide Vision Loss Risk

A 2024 retrospective, matched cohort study of 16,827 neuro-ophthalmic patients at Massachusetts Eye and Ear in Boston found patients taking semaglutide had significantly higher rates of NAION compared to those taking other medications. Among diabetes patients, about 9% of semaglutide users developed NAION over three years versus only 2% of those taking other diabetes drugs, meaning semaglutide users were over 4 times more likely to experience this condition. For those using semaglutide for weight loss, nearly 7% developed NAION compared to less than 1% of those taking other weight-loss medications, making semaglutide users over 7 times more likely to develop the eye condition. While these risk increases are substantial, it's important to note that NAION remained uncommon overall.

A much larger February 2025 retrospective study of 37 million diabetes patients across 14 databases found that about 14-15 cases of vision problems (NAION) per 100,000 patients yearly were reported in semaglutide users. Compared to other diabetes drugs, semaglutide showed no significant difference in risk for most comparisons, though one analysis found a 32% increased risk when patients were compared to themselves before starting the medication. The absolute risk remained very low overall.

Implications for Other GLP-1 Receptor Agonists

The vision loss risk may extend beyond semaglutide to other GLP-1 receptor agonist medications. The February 2025 study found that semaglutide users did not have significantly higher NAION risk compared to patients taking other GLP-1 RA drugs, suggesting this may be a class-wide effect rather than specific to semaglutide alone. This means other GLP-1 medications like liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), and tirzepatide (Mounjaro, Zepbound) may carry similar vision loss risks.

However, research specifically examining NAION rates with these other GLP-1 receptor agonists is limited. The mechanism behind the potential GLP-1 RA and NAION association remains unknown, making it unclear whether the risk varies between different medications in this drug class. Patients taking any GLP-1 receptor agonist should be aware of this potential risk and discuss vision changes with their healthcare providers, though the absolute risk remains low across all these medications.

Related questions

What is NAION?

NAION typically causes sudden vision loss in one eye due to reduced blood flow to the optic nerve, damaging neurons that transmit visual information to the brain. While serious, NAION remains a rare condition.

Medical Expert Recommendations

Researchers emphasize that GLP-1 receptor agonists provide substantial benefits, including improved diabetes management, significant weight loss, reduced cardiovascular events, and decreased mortality. Expert advice currently recommends that patients should not stop semaglutide based solely on NAION risk, given the medication's proven therapeutic benefits and the condition's low absolute risk.
However, added caution is recommended for patients with previous vision loss from any cause who are considering semaglutide treatment.

Bottom Line

While studies suggest an association between semaglutide and NAION, the absolute risk remains very low. The mechanism behind this potential connection is not yet understood, and more research is needed to establish causality. Patients should discuss these findings with their healthcare providers to weigh individual risks and benefits.

References
  • Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. 2024;142(8):732–739. doi:10.1001/jamaophthalmol.2024.2296
  • Cai CX, Hribar M, Baxter S, et al. Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. JAMA Ophthalmol. 2025;143(4):304–314. doi:10.1001/jamaophthalmol.2024.6555

Read next

Tirzepatide vs semaglutide: How do they compare?

Both tirzepatide and semaglutide are prescription medicines used with diet and exercise to treat people with type 2 diabetes or to help people lose and maintain weight loss. Tirzepatide is also approved by the FDA to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity, while semaglutide is approved to reduce the risk of serious heart problems and to help reduce the risk of worsening kidney disease.

Continue reading

Can you get tirzepatide from a compounding pharmacy?

Tirzepatide cannot be legally compounded in a U.S. pharmacy at this time. It has been removed from the FDA drug shortage list as of October 2, 2024. When drugs are in short supply, the FDA may allow temporary compounding of some medicines to allow patients to continue to access their treatments. Tirzepatide is now widely available as a prescription medicine made by Eli Lilly under the brands names Mounjaro (for type 2 diabetes) and Zepbound (for weight loss and sleep apnea).

Continue reading

Why am I not losing weight on Ozempic?

Although Ozempic is not FDA-approved for weight loss, over 86% of people lose at least 5% of their body weight in trials that have studied semaglutide, the active ingredient of Ozempic. But the same clinical trials also show that just under 14% don’t lose weight, and some may even gain weight. Continue reading

See also:

Related medical questions

Drug information

Related support groups